106 Commerce Street, Suite 105
Lake Mary, FL 32746
TEL: 407.878.7606 • FAX: 407.878.7611
Order additional copies at GuidelineCentral.com
Copyright © 2022 All rights reserved
ASCONEO03224b
Disclaimer
is pocket guide is derived om recommendations in the American Society of Clinical Oncolog y
Guideline. is resource is a practice tool based on ASCO
®
practice guidelines and is not intended
to substitute for the independent professional judgment of the treating physician. Practice guidelines do
not account for individual variation among patients. is pocket guide does not purport to suggest any
particular course of medical treatment. Use of the practice guidelines and this resource are voluntary.
e practice guidelines and additional information are available at www.asco.org/breast-cancer-
guidelines. Copyright © 2022 by American Society of Clinical Oncolog y. All rights reserved.
Abbreviations
ALND, axillary lymph node dissection; BCS, breast conserving surgery; IBC, inflammatory
breast cancer; pCR, pathologic complete response; TNBC, triple negative breast cancer; TIL,
tumor infiltrating lymphocyte
Source
Korde LA, Somerfield MR, Hershman DL, et al. Neoadjuvant Chemotherapy, Endocrine
erapy, and Targeted erapy for Breast Cancer Guideline Expert Panel. Use of Immune
Checkpoint Inhibitor Pembrolizumab in the Treatment of High-risk, Early-stage Triple
Negative Breast Cancer: ASCO Guideline Rapid Recommendation Update. J Clin Oncol.
2022 April 13. doi: 10.1200/JCO.22.00503
Korde LA, Somerfield MR, Carey LA, et al. Neoadjuvant Chemotherapy, Endocrine
erapy, and Targeted erapy for Breast Cancer: ASCO Guideline. J Clin Oncol.
2021 May 1;39(13):1485-1505
ASCO believes that cancer clinical trials are vital to inform medical decisions and
improve cancer care and that all patients should have the opportunity to participate.
Additional information, which may include data supplements, slide sets, and other clinical
tools and resources, is available at www.asco.org/breast-cancer-guidelines.
